Help appealing denials for this BTK inhibitor for chronic hives.

Appeal Your Rhapsido Denial

Get access to this first oral BTK inhibitor for chronic spontaneous urticaria.

Understanding Your Rhapsido (remibrutinib) Denial

Rhapsido (remibrutinib) is the first and only BTK inhibitor approved for chronic spontaneous urticaria (CSU) in adults who have not responded adequately to antihistamines. CSU causes persistent, unpredictable hives that significantly impact quality of life. If antihistamines haven't controlled your hives, you deserve access to this targeted therapy.

Common Reasons for Denial

! Prior authorization required
! Must try multiple antihistamines first
! Must try omalizumab (Xolair) first
! Step therapy requirement not met
! Inadequate documentation of antihistamine failure
! Specialty tier drug not covered

How We Help

We help you document your history of antihistamine use, hive severity and frequency, impact on quality of life, and prior treatment failures to demonstrate medical necessity for Rhapsido.

Start your Rhapsido appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Remibrutinib is a highly selective BTK inhibitor that blocks mast cell activation, reducing hive formation and itching.

✓ Clinical trials demonstrated significant improvement in urticaria symptoms and quality of life in patients with inadequate response to antihistamines.

✓ Chronic spontaneous urticaria affects quality of life comparable to severe heart disease or asthma.

✓ Oral targeted therapy offers improved convenience and tolerability compared to injectable biologics for some patients.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Novartis Patient Support (Rhapsido)

Eligible commercially insured patients may pay as little as $0 through Co-Pay Plus. Bridge Program provides free medication for up to 12 months while awaiting insurance approval. Call Novartis Patient Support.

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

Asthma and Allergy Foundation of America

Leading patient advocacy for allergic conditions including chronic urticaria.

We CU

Nonprofit dedicated to empowering those affected by chronic urticaria.

Frequently Asked Questions

Most insurers require you to have tried and failed H1 antihistamines (like cetirizine, loratadine, or fexofenadine) at standard and often higher doses. Some may also require trial of omalizumab (Xolair). Document all treatments tried and why they failed.

Track your hives using a diary noting daily hive count, itching severity, sleep disruption, and impact on work/activities. The Urticaria Activity Score (UAS7) is commonly used to document disease severity.

Ready to Fight Your Rhapsido (remibrutinib) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Novartis AG. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.